We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02103335
Recruitment Status : Completed
First Posted : April 3, 2014
Last Update Posted : November 22, 2017
Celgene Corporation
Information provided by (Responsible Party):

Brief Summary:

This is a Phase 1 clinical trial to evaluate a new combination of drugs for the treatment of relapsed or refractory (drug-resistant) multiple myeloma. The drugs being studied are:

  • Pomalidomide (POMALYST®) is a drug that affects the immune system (an immunomodulatory drug) that has been approved by the United States (US) Food and Drug Administration (FDA) for the treatment of multiple myeloma.
  • Marizomib is an investigational drug being developed by Triphase that is being studied for the treatment of multiple myeloma. Investigational drugs are drugs that have not yet been approved by health authorities, such as the FDA, for general use but have been approved for use in specific clinical studies. Marizomib inhibits a cellular machine called the proteasome, which destroys unnecessary or damaged proteins. Other proteasome inhibitors have been shown to be effective in the treatment of multiple myeloma.
  • Dexamethasone is a corticosteroid drug that affects the immune system (an immunomodulatory drug) that has been approved by the FDA for the treatment of multiple myeloma.

This is the first study to evaluate the three-drug combination of pomalidomide (POM), marizomib (MRZ), and dexamethasone (LD-DEX) in humans. Pomalidomide, alone or in combination with dexamethasone, is approved by the FDA for the treatment of relapsed or refractory multiple myeloma.

The primary objective of this study is to determine the best drug dosing levels for this three-drug combination, including the highest safe doses and/or the recommended doses for future clinical studies of this drug combination. The secondary purposes of this study are to determine the safety of this drug combination and its effectiveness in treating relapsed or refractory multiple myeloma. The study will include examination of levels of all three drugs in the blood during various time points during treatment.

Condition or disease Intervention/treatment Phase
Multiple Myeloma in Relapse Refractory Multiple Myeloma Multiple Myeloma Drug: pomalidomide Drug: marizomib Drug: low-dose dexamethasone Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 38 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Actual Study Start Date : June 5, 2014
Actual Primary Completion Date : October 3, 2016
Actual Study Completion Date : November 30, 2016

Arm Intervention/treatment
Experimental: Single Group Assignment
Combination Pomalidomide, low-dose Dexamethasone, and Marizomib:
Drug: pomalidomide
Oral Pomalidomide, days 1-21 of 28 day cycle, dose 3 to 4 mg
Other Name: POMALYST

Drug: marizomib
IV Marizomib, 0.2 to 0.5 mg/m2 on days 1, 4, 8, 11 of 28 day cycle
Other Name: NPI-0052

Drug: low-dose dexamethasone
Oral Dexamethasone, days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 22, 23 of 28 day cycle, 5 or 10 mg

Primary Outcome Measures :
  1. Maximum tolerated dose and/or recommended Phase 2 dose [ Time Frame: Continuous up to one year ]

Secondary Outcome Measures :
  1. Adverse events [ Time Frame: Up to 5 years ]
  2. Response rate [ Time Frame: Up to 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

Subjects must meet the following criteria to be eligible for study participation:

  1. At least 18 years at the time of signing the informed consent form.
  2. Able to understand and voluntarily sign an informed consent form prior to any study-related assessments/procedures.
  3. Able to adhere to the study visit schedule and other protocol requirements.
  4. Documented diagnosis of multiple myeloma and measurable disease by serum or urine protein electrophoresis (SPEP or UPEP): SPEP ≥0.5 g/dL, UPEP ≥200 mg/24 hours, or involved serum free light chain (FLC) level ≥10 mg/dL provided the serum FLC ratio is abnormal.
  5. Previously received 1 or more lines of anti-myeloma therapy that must have included both lenalidomide and bortezomib (either separately or in combination).
  6. Documented disease progression during or within 60 days after their most recent line of anti myeloma therapy.
  7. Eastern Cooperative Oncology Group (ECOG) performance status score ≤2.
  8. All study participants in the USA must be registered into the mandatory POMALYST REMS™ (Risk Evaluation & Mitigation Strategy) program, and be willing and able to comply with the requirements of the POMALYST REMS™ program.
  9. All study participants in the USA who are females of child-bearing potential (FCBP) must adhere to the scheduled pregnancy testing as required in the POMALYST REMS™ program.
  10. All study participants outside the USA must agree to comply with the POMALYST® PPRMP requirements.
  11. All subjects must be able and agree to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight heparin).
  12. For females of child bearing potential (FCBP): Agree to use 2 reliable forms of contraception simultaneously or practice complete abstinence from heterosexual contact for at least 28 days before starting study treatment, while participating in the study (including dose interruptions), and for at least 28 days after study treatment discontinuation; must follow pregnancy testing requirements as outlined in the POMALYST REMS™ program or the PPRMP.
  13. For all females: Agree to abstain from breastfeeding during study participation and for at least 28 days after study treatment discontinuation.
  14. For all males: Agree to use a latex or synthetic condom during any sexual contact with FCBP while participating in the study and for at least 28 days following discontinuation from study treatment, even if he has undergone a successful vasectomy.
  15. For all males: Agree to refrain from donating semen or sperm while on study and for at least 28 days after discontinuation from study treatment.
  16. Refrain from donating blood while on study treatment and for at least 28 days after discontinuation from study treatment.
  17. Agree not to share medication.

Exclusion Criteria

Subjects with any of the following will be excluded from participation in the study:

  1. Peripheral neuropathy Grade ≥2.
  2. Non-secretory multiple myeloma.
  3. Any of the following laboratory abnormalities:

    • ANC <1,000/µL;
    • Platelet count <50,000/µL for subjects in whom <50% of bone marrow nucleated cells are plasma cells; or a platelet count <30,000/µL for subjects in whom ≥50% of bone marrow nucleated cells are plasma cells;
    • Creatinine clearance (CrCL) <45 mL/min as measured directly or as calculated according to Cockcroft Gault formula;
    • Corrected serum calcium >13.5 mg/dL (>3.4 mmol/L);
    • Hemoglobin <8 g/dL (<4.9 mmol/L; prior red blood cell [RBC] transfusion or recombinant human erythropoietin use is permitted before study entry);
    • Serum aspartate aminotransferase (AST) >3.0 x upper limit of normal (ULN);
    • Serum alanine aminotransferase (ALT) >3.0 x ULN;
    • Serum total bilirubin >1.5 x ULN (>3.0 x ULN for subjects with known Gilbert's disease).
  4. Prior history of malignancies, other than MM, unless the subject has been free of the disease for ≥5 years. Subjects may be entered earlier than 5 years if they have received curative treatment for the following:

    • Basal cell carcinoma of the skin;
    • Squamous cell carcinoma of the skin;
    • Carcinoma in situ of the cervix;
    • Carcinoma in situ of the breast;

    Or if they have:

    o Incidental histologic finding of prostate cancer (T1a or T1b using the TNM [tumor, nodes, metastasis] clinical staging system) or non metastatic prostate cancer that is in complete remission or does not require treatment.

  5. Previous therapy with POM and/or MRZ.
  6. History of allergic reaction or hypersensitivity to thalidomide, lenalidomide, bortezomib, carfilzomib, boron, mannitol, or DEX.
  7. Grade ≥3 rash during prior thalidomide or lenalidomide therapy.
  8. Gastrointestinal disease that may significantly alter the absorption of POM.
  9. History of the following:

    • Congestive heart failure of Class III or IV of the New York Heart Association (NYHA) classification;
    • Myocardial infarction within 12 months prior to starting study treatment;
    • Unstable or poorly controlled angina pectoris, including Prinzmetal variant angina pectoris.
  10. Any of the following within 14 days prior to initiation of study treatment:

    • Plasmapheresis;
    • Major surgery (kyphoplasty is not considered major surgery);
    • Radiation therapy;
    • Anti-myeloma drug therapy.
  11. Received any investigational agents within 28 days or 5 half-lives (whichever is longer) prior to initiation of study treatment.
  12. Conditions requiring chronic steroid or immunosuppressive treatment (eg, rheumatoid arthritis, multiple sclerosis, or lupus), which likely need additional steroid or immunosuppressive treatments in addition to the study treatment.
  13. Subjects may not receive corticosteroids (>10 mg/day of prednisone or equivalent) within 3 weeks prior to enrollment (use of steroidal inhalation aerosol for asthma is permitted).
  14. Unable or unwilling to undergo antithrombotic prophylactic treatment.
  15. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study, as determined by the Investigator.
  16. Pregnant and/or breastfeeding females.
  17. Known seropositive for or active viral infection with human immunodeficiency virus (HIV).
  18. Known seropositive for or active viral infection with hepatitis B virus (HBV), with the following exceptions:

    • negative are eligible.
    • Subjects who had hepatitis B but have received an antiviral treatment and show non-detectable viral DNA for 6 months are eligible.
    • Subjects who are seropositive because of hepatitis B virus vaccine are eligible.
  19. Known seropositive for or active viral infection with hepatitis C virus (HCV), with the following exception: Subjects who had hepatitis C but have received an antiviral treatment and show no detectable viral ribonucleic acid (RNA) for 6 months are eligible.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02103335

Layout table for location information
United States, Illinois
University of Chicago Medical Center
Chicago, Illinois, United States, 60637
United States, Maryland
University of Maryland
Baltimore, Maryland, United States, 20201
United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
United States, Michigan
Karmanos Cancer Center
Detroit, Michigan, United States, 48201
Australia, Victoria
Peter MacCallum Cancer Centre
East Melbourne, Victoria, Australia, 3002
Alfred Hospital
Prahran, Victoria, Australia, 3181
Sponsors and Collaborators
Celgene Corporation
Layout table for investigator information
Study Director: Steven D Reich, MD Triphase Research and Development I Corp
Dexamethasone Prescribing Information. Roxane Laboratories Inc., Columbus, OH; Sep 2007. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase= renetnt&folderPath=/Prescribing+Information/PIs/Roxane/Dexamethasone/Dexamethasone+Tablets+Solution+and+Intensol.pdf. Accessed 20 September 2013.
Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975 2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009_pops09/. Accessed 20 September 2013.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. http://www.cap.org/apps/docs/committees/immunology/myeloma.pdf. Multiple Myeloma (V.1.2011), 201. Accessed 20 September 2013.
Richardson PG, Jagannath S, Jakubowiak A, et al. Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone in Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After > 2 Years of Follow-up. 2010b; ASH Annual Meeting Abstract #3049.
Velcade® (bortezomib) for Injection Prescribing Information. Millennium Pharmaceuticals Inc., Cambridge, MA; V-12-0388 02/13. http://www.velcade-hcp.com/previously-untreated-multiple-myeloma/dosing.aspx?gclid=CPD4lKn2tbsCFcU5Qgod9R0AdA.

Layout table for additonal information
Responsible Party: Celgene
ClinicalTrials.gov Identifier: NCT02103335    
Other Study ID Numbers: NPI-0052-107
First Posted: April 3, 2014    Key Record Dates
Last Update Posted: November 22, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Celgene:
Multiple Myeloma
Low dose Dexamethasone
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Immunologic Factors
Angiogenesis Inhibitors
Angiogenesis Modulating Agents